Form 4 · Filed May 4, 2026, 09:27 PM UTC
EBS/Emergent BioSolutions Inc.
Fowler Neal Franklin — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | A | other | 25,344 | $0 | — | 160,847 |
| Apr 30, 2026 | A | other | 11,296 | $0 | — | 11,296 |
Source: SEC EDGAR raw filing ↗ · Accession 0001493692-26-000003